Abstract:The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause for the ongoing global public health emergency. It is more commonly known as coronavirus disease 2019 (COVID-19); the pandemic threat continues to spread aroundthe world with the fluctuating emergence of its new variants. The severity of COVID-19 ranges from asymptomatic to serious acute respiratory distress syndrome (ARDS), which has led to a high human mortality rate and disruption of socioeconomic well-being. For the restoration of pre-pandemic normalcy, the international scientific community has been conducting research on a war footing to limit extremely pathogenic COVID-19 through diagnosis, treatment, and immunization. Since the first report of COVID-19 viral infection, an array of laboratory-based and point-of-care (POC) approaches have emerged for diagnosing and understanding its status of outbreak. The RT-PCR-based viral nucleic acid test (NAT) is one of the rapidly developed and most used COVID-19 detection approaches. Notably, the current forbidding status of COVID-19 requires the development of safe, targeted vaccines/vaccine injections (shots) that can reduce its associated morbidity and mortality. Massive and accelerated vaccination campaigns would be the most effective and ultimate hope to end the COVID-19 pandemic. Since the SARS-CoV-2 virus outbreak, emerging biotechnologies and their multidisciplinary approaches have accelerated the understanding of molecular details as well as the development of a wide range of diagnostics and potential vaccine candidates, which are indispensable to combating the highly contagious COVID-19. Several vaccine candidates have completed phase III clinical studies and are reported to be effective in immunizing against COVID-19 after their rollout via emergency use authorization (EUA). However, optimizing the type of vaccine candidates and its route of delivery that works best to control viral spread is crucial to face the threatening variants expected to emerge over time. In conclusion, the insights of this review would facilitate the development of more likely diagnostics and ideal vaccines for the global control of COVID-19.

A Review on DNA Vaccines in Pre-Clinical Trials Against SARS-CoV-2

COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective

The development of DNA vaccines against SARS-CoV-2

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

A review on covid-19: From molecular variability, drug development to status of vaccine clinical trials

Nucleic Acid Vaccines against SARS-CoV-2

Progress in SARS-CoV-2, Diagnostic and Clinical Treatment of COVID-19

COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

Viral vector and nucleic acid vaccines against COVID-19: A narrative review

RNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 Infection

COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2

Development of SARS-CoV-2 Vaccine: Challenges and Prospects

DNA Vaccines: Their Formulations, Engineering and Delivery

Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine

Understanding the SARS-CoV-2 virus to mitigate current and future pandemic(s)

An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

Tracking the COVID-19 vaccines: The global landscape

Coronavirus (SARS-CoV-2): a systematic review for potential vaccines

Advances in gene-based vaccine platforms to address the COVID-19 pandemic